62 related articles for article (PubMed ID: 38379108)
1. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.
Pacis S; Bolzani A; Heuck A; Gossens K; Kruse M; Fritz B; Maywald U; Wilke T; Kunz C
Oncol Ther; 2024 Feb; ():. PubMed ID: 38379108
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
5. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
6. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
7. The evolving therapy of DLBCL: Bispecific antibodies.
Hutchings M
Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database.
Borchmann P; Heger JM; Mahlich J; Papadimitrious MS; Riou S; Werner B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7091-7101. PubMed ID: 36871091
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Role of Radiation Therapy in DLBCL: From Early-Stage to Refractory Disease.
Jones G; Plastaras JP; Ng AK; Kelsey CR
Oncology (Williston Park); 2022 Dec; 36(12):718-727. PubMed ID: 36548096
[TBL] [Abstract][Full Text] [Related]
10. Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population.
Vic S; Lemoine J; Armand P; Lemonnier F; Houot R
Eur J Cancer; 2022 Nov; 175():246-253. PubMed ID: 36166850
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
